Can cognitive enhancers reduce the risk of falls in older people with mild cognitive impairment? A protocol for a randomised controlled double blind trial

Manuel Montero-Odasso, Jennie L Wells, Michael J Borrie, Mark Speechley, Manuel Montero-Odasso, Jennie L Wells, Michael J Borrie, Mark Speechley

Abstract

Background: Older adults with cognitive problems have a higher risk of falls, at least twice that of cognitively normal older adults. The consequences of falls in this population are very serious: fallers with cognitive problems suffer more injuries due to falls and are approximately five times more likely to be admitted to institutional care. Although the mechanisms of increased fall risk in cognitively impaired people are not completely understood, it is known that impaired cognitive abilities can reduce attentional resource allocation while walking. Since cognitive enhancers, such as cholinesterase inhibitors, improve attention and executive function, we hypothesise that cognitive enhancers may reduce fall risk in elderly people in the early stages of cognitive decline by improving their gait and balance performance due to an enhancement in attention and executive function.

Method/design: Double blinded randomized controlled trial with 6 months follow-up in 140 older individuals with Mild Cognitive Impairment (MCI). Participants will be randomized to the intervention group, receiving donepezil, and to the control group, receiving placebo. A block randomization by four and stratification based on fall history will be performed. Primary outcomes are improvements in gait velocity and reduction in gait variability. Secondary outcomes are changes in the balance confidence, balance sway, attention, executive function, and number of falls.

Discussion: By characterizing and understanding the effects of cognitive enhancers on fall risk in older adults with cognitive impairments, we will be able to pave the way for a new approach to fall prevention in this population. This RCT study will provide, for the first time, information regarding the effect of a medication designed to augment cognitive functioning have on the risk of falls in older adults with Mild Cognitive Impairment. We expect a significant reduction in the risk of falls in this vulnerable population as a function of the reduced gait variability achieved by treatment with cognitive enhancers. This study may contribute to a new approach to prevent and treat fall risk in seniors in early stages of dementia.

Trial registration: The protocol for this study is registered with the Clinical Trials Registry, identifier number: NCT00934531 http://www.clinicaltrials.gov.

Figures

Figure 1
Figure 1
Regulation and Neural Control of Gait.
Figure 2
Figure 2
Changes in Gait Velocity in people with early Alzheimer's disease (AD) taking donepezil (intervention group) and Mild Cognitive Impairment (MCI; control group).
Figure 3
Figure 3
Trial Design. Adapted from the CONSORT diagram [61,62].
Figure 4
Figure 4
Schematic timeline of the proposed RCT.

References

    1. Canadian Study of Health and Aging Working Group. Canadian study of health and aging: study methods and prevalence of dementia. CMAJ. 1994;150:899–913.
    1. Third Canadian Consensus Conference on Diagnosis and Treatment of Dementia.
    1. Thomas VS, Darvesh S, MacKnight C, Rockwood K. Estimating the prevalence of dementia in elderly people: a comparison of the Canadian Study of Health and Aging and National Population Health Survey approaches. Int Psychogeriatr. 2001;13(Supp 1):169–175. doi: 10.1017/S1041610202008116.
    1. Rosano C, Brach J, Longstreth WT Jr, Newman AB. Quantitative measures of gait characteristics indicate prevalence of underlying subclinical structural brain abnormalities in high-functioning older adults. Neuroepidemiology. 2006;26:52–60. doi: 10.1159/000089240.
    1. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. 1988;319:1701–1707.
    1. Morris JC, Rubin EH, Morris EJ, Mandel SA. Senile dementia of the Alzheimer's type: an important risk factor for serious falls. J Gerontol. 1987;42:412–417.
    1. Woollacott M, Shumway-Cook A. Attention and the control of posture and gait: a review of an emerging area of research. Gait Posture. 2002;16:1–14. doi: 10.1016/S0966-6362(01)00156-4.
    1. Yogev-Seligmann G, Hausdorff JM, Giladi N. The role of executive function and attention in gait. Mov Disord. 2008;23:329–342. doi: 10.1002/mds.21720.
    1. Aggarwal NT, Wilson RS, Beck TL, Bienias JL, Bennett DA. Mild cognitive impairment in different functional domains and incident Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2005;76:1479–1484. doi: 10.1136/jnnp.2004.053561.
    1. Burns A, Zaudig M. Mild cognitive impairment in older people. Lancet. 2002;360:1963–1965. doi: 10.1016/S0140-6736(02)11920-9.
    1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–308. doi: 10.1001/archneur.56.3.303.
    1. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A. et al.Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379–2388. doi: 10.1056/NEJMoa050151.
    1. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O. et al.Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256:240–246. doi: 10.1111/j.1365-2796.2004.01380.x.
    1. Lopez OL, Jagust WJ, DeKosky ST, Becker JT, Fitzpatrick A, Dulberg C, Breitner J, Lyketsos C, Jones B, Kawas C. et al.Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol. 2003;60:1385–1389. doi: 10.1001/archneur.60.10.1385.
    1. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985–1992. doi: 10.1001/archneur.58.12.1985.
    1. Liu-Ambrose TY, Ashe MC, Graf P, Beattie BL, Khan KM. Canadian study of health and aging: study methods and prevalence of dementia. Phys Ther. 2008;88:1482–1491.
    1. Hausdorff JM, Yogev G, Springer S, Simon ES, Giladi N. Walking is more like catching than tapping: gait in the elderly as a complex cognitive task. Exp Brain Res. 2005;164:541–548. doi: 10.1007/s00221-005-2280-3.
    1. Lundin-Olsson L, Nyberg L, Gustafson Y. "Stops walking when talking" as a predictor of falls in elderly people. Lancet. 1997;349:617. doi: 10.1016/S0140-6736(97)24009-2.
    1. Beauchet O, Dubost V, Gonthier R, Kressig RW. Dual-task-related gait changes in transitionally frail older adults: the type of the walking-associated cognitive task matters. Gerontology. 2005;51:48–52. doi: 10.1159/000081435.
    1. Ble A, Volpato S, Zuliani G, Guralnik JM, Bandinelli S, Lauretani F, Bartali B, Maraldi C, Fellin R, Ferrucci L. Executive function correlates with walking speed in older persons: the InCHIANTI study. J Am Geriatr Soc. 2005;53:410–415. doi: 10.1111/j.1532-5415.2005.53157.x.
    1. Bootsma-van der Wiel A, Gussekloo J, de Craen AJ, van Exel E, Bloem BR, Westendorp RG. Walking and talking as predictors of falls in the general population: the Leiden 85-Plus Study. J Am Geriatr Soc. 2003;51:1466–1471. doi: 10.1046/j.1532-5415.2003.51468.x.
    1. Camicioli R, Howieson D, Lehman S, Kaye J. Talking while walking: the effect of a dual task in aging and Alzheimer's disease. Neurology. 1997;48:955–958.
    1. Camicioli R, Bouchard T, Licis L. Dual-tasks and walking fast: Relationship to extra-pyramidal signs in advanced Alzheimer disease. J Neurol Sci. 2006;248:205–209. doi: 10.1016/j.jns.2006.05.013.
    1. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183–194. doi: 10.1111/j.1365-2796.2004.01388.x.
    1. Ritchie K, Touchon J. Mild cognitive impairment: conceptual basis and current nosological status. Lancet. 2000;355:225–228. doi: 10.1016/S0140-6736(99)06155-3.
    1. Montero-Odasso M, Bergman H, Phillips NA, Wong C, Sourial N, Chertkow H. The effect of executive and memory dysfunction in gait performance in a cognitive impairment population. J Am Geriatric Soc. 2006;54:S154.
    1. Hausdorff JM. Gait variability: methods, modeling and meaning. J Neuroeng Rehabil. 2005;2:19. doi: 10.1186/1743-0003-2-19.
    1. Herman T, Giladi N, Gurevich T, Hausdorff JM. Gait instability and fractal dynamics of older adults with a "cautious" gait: why do certain older adults walk fearfully? Gait Posture. 2005;21:178–185. doi: 10.1016/j.gaitpost.2004.01.014.
    1. Paleacu D, Shutzman A, Giladi N, Herman T, Simon ES, Hausdorff JM. Effects of pharmacological therapy on gait and cognitive function in depressed patients. Clin Neuropharmacol. 2007;30:63–71. doi: 10.1097/01.wnf.0000240949.41691.95.
    1. Guideline for the prevention of falls in older persons. American Geriatrics Society, British Geriatrics Society, and American Academy of Orthopaedic Surgeons Panel on Falls Prevention. J Am Geriatr Soc. 2001;49:664–672. doi: 10.1046/j.1532-5415.2001.49115.x.
    1. Oliver D, Connelly JB, Victor CR, Shaw FE, Whitehead A, Genc Y, Vanoli A, Martin FC, Gosney MA. Strategies to prevent falls and fractures in hospitals and care homes and effect of cognitive impairment: systematic review and meta-analyses. BMJ. 2007;334:82. doi: 10.1136/bmj.39049.706493.55.
    1. Shaw FE, Bond J, Richardson DA, Dawson P, Steen IN, McKeith IG, Kenny RA. Multifactorial intervention after a fall in older people with cognitive impairment and dementia presenting to the accident and emergency department: randomised controlled trial. BMJ. 2003;326:73. doi: 10.1136/bmj.326.7380.73.
    1. Shaw FE. Prevention of falls in older people with dementia. J Neural Transm. 2007;114:1259–1264. doi: 10.1007/s00702-007-0741-5.
    1. Seltzer B, Zolnouni P, Nunez M, Goldman R, Kumar D, Ieni J, Richardson S. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol. 2004;61:1852–1856. doi: 10.1001/archneur.61.12.1852.
    1. Assal F, Allali G, Kressig RW, Herrmann FR, Beauchet O. Galantamine improves gait performance in patients with Alzheimer's disease. J Am Geriatr Soc. 2008;56:946–947. doi: 10.1111/j.1532-5415.2008.01657.x.
    1. Pahapill PA, Lozano AM. The pedunculopontine nucleus and Parkinson's disease. Brain. 2000;123(Pt 9):1767–1783. doi: 10.1093/brain/123.9.1767.
    1. Bohnen N, Kaufer D, Hendrickson R, Ivanco L, Moore R, DeKosky S. Effects of donepezil on motor function in patients with Alzheimer disease. J Clin Psychopharmacol. 2004;24:354–356. doi: 10.1097/01.jcp.0000126665.88905.6a.
    1. Montero-Odasso M, Wells J, Borrie M. Can cognitive enhancers reduce the risk of falls in people with dementia? An open-label study with controls. J Am Geriatr Soc. 2009;57:359–360. doi: 10.1111/j.1532-5415.2009.02085.x.
    1. Powell LE, Myers AM. The Activities-specific Balance Confidence (ABC) Scale. J Gerontol A Biol Sci Med Sci. 1995;50A:M28–M34.
    1. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, Brown C, Cooke TD, Daniel W, Feldman D. et al.The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 1991;34:505–514. doi: 10.1002/art.1780340502.
    1. Altman RD. Criteria for the classification of osteoarthritis of the knee and hip. Scand J Rheumatol Suppl. 1987;65:31–39. doi: 10.3109/03009748709102175.
    1. Altman RD, Block DA, Brandt KD, Cooke DV, Greenwald RA, Hochberg MC, Howell DS, Ike RW, Kaplan D, Koopman W. et al.Osteoarthritis: definitions and criteria. Ann Rheum Dis. 1990;49:201. doi: 10.1136/ard.49.3.201-a.
    1. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17:37–49. doi: 10.1016/0022-3956(82)90033-4.
    1. Yesavage JA. Geriatric Depression Scale. Psychopharmacol Bull. 1988;24:709–711.
    1. Chertkow H. Mild cognitive impairment. Curr Opin Neurol. 2002;15:401–407. doi: 10.1097/00019052-200208000-00001.
    1. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–699. doi: 10.1111/j.1532-5415.2005.53221.x.
    1. Muir SW, Berg K, Chesworth B, Speechley M. Use of the Berg Balance Scale for predicting multiple falls in community-dwelling elderly people: a prospective study. Phys Ther. 2008;88:449–459.
    1. Speechley M, Belfry S, Borrie MJ, Jenkyn KB, Crilly R, Gill DP, McLean S, Stolee P, Vandervoort AA, Jones GR. Risk factors for falling among community-dwelling veterans and their caregivers. Can J Aging. 2005;24:261–274.
    1. Hittmair-Delazer M, Semenza C, Denes G. Concepts and facts in calculation. Brain. 1994;117(Pt 4):715–728. doi: 10.1093/brain/117.4.715.
    1. Verghese J, Kuslansky G, Holtzer R, Katz M, Xue X, Buschke H, Pahor M. Walking while talking: effect of task prioritization in the elderly. Arch Phys Med Rehabil. 2007;88:50–53. doi: 10.1016/j.apmr.2006.10.007.
    1. Myers AM, Powell LE, Maki BE, Holliday PJ, Brawley LR, Sherk W. Psychological indicators of balance confidence: relationship to actual and perceived abilities. J Gerontol A Biol Sci Med Sci. 1996;51:M37–M43.
    1. Lord SR, Clark RD, Webster IW. Postural stability and associated physiological factors in a population of aged persons. J Gerontol. 1991;46:M69–M76.
    1. Montero-Odasso M, Casas A, Hansen K, Gutmanis I, Wells J, Borrie M. Test-Retest Reliability of Quantitative Gait Analysis in People with Mild Cognitive Impairment. Canadian Journal of Geriatric Medicine & Psychiatry. 2007;10:33–34.
    1. Bilney B, Morris M, Webster K. Concurrent related validity of the GAITRite walkway system for quantification of the spatial and temporal parameters of gait. Gait Posture. 2003;17:68–74. doi: 10.1016/S0966-6362(02)00053-X.
    1. van Uden CJ, Besser MP. Test-retest reliability of temporal and spatial gait characteristics measured with an instrumented walkway system (GAITRite) BMC Musculoskelet Disord. 2004;5:13. doi: 10.1186/1471-2474-5-13.
    1. Youdas JW, Hollman JH, Aalbers MJ, Ahrenholz HN, Aten RA, Cremers JJ. Agreement between the GAITRite walkway system and a stopwatch-footfall count method for measurement of temporal and spatial gait parameters. Arch Phys Med Rehabil. 2006;87:1648–1652. doi: 10.1016/j.apmr.2006.09.012.
    1. Gill DP, Zou GY, Jones GR, Speechley M. Injurious falls are associated with lower household but higher recreational physical activities in community-dwelling older male veterans. Gerontology. 2008;54:106–115. doi: 10.1159/000116113.
    1. Gill DP, Jones GR, Zou GY, Speechley M. The Phone-FITT: a brief physical activity interview for older adults. J Aging Phys Act. 2008;16:292–315.
    1. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006. p. CD005593.
    1. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2006. p. CD001190.
    1. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gotzsche PC, Lang T. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134:663–694.
    1. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357:1191–1194. doi: 10.1016/S0140-6736(00)04337-3.
    1. Tinetti ME, Baker DI, McAvay G, Claus EB, Garrett P, Gottschalk M. et al.A multifactorial intervention to reduce the risk of falling among elderly people living in the community. N Engl J Med. 1994;331:821–827. doi: 10.1056/NEJM199409293311301.
    1. Ganz DA, Higashi T, Rubenstein LZ. Monitoring falls in cohort studies of community-dwelling older people: effect of the recall interval. J Am Geriatr Soc. 2005;53:2190–2194. doi: 10.1111/j.1532-5415.2005.00509.x.
    1. Hochberg Y, Sharper A. Bonferroni Procedure for Multiple Tests of Significance. Biometrika. 1988;75:800–8002. doi: 10.1093/biomet/75.4.800.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe